Clinical reference Biomarker Directory
Back to directory

Anti-gliadin antibody IgA

Established

Anti-gliadin IgA is an outdated celiac disease marker superseded by tTG-IgA testing.

Also known as AGA IgA anti-gliadin IgA
In plain language

This older test for celiac disease is no longer considered reliable. Newer, more accurate blood tests (like tTG-IgA) have replaced it, so a result from this older test alone shouldn't be used to diagnose celiac disease.

Biomarker & context

Anti-gliadin IgA antibodies target gliadin, a component of gluten, and were historically used to screen for celiac disease, an autoimmune reaction to gluten damaging the small intestine.

What it indicates

Current professional guidance (AACC, ACG) states anti-gliadin antibody testing has low diagnostic accuracy and is no longer recommended for detecting celiac disease, having been superseded by more accurate tests.

Diagnosis & clinical testing

Anti-tissue transglutaminase (tTG) IgA is now the recommended first-line test for suspected celiac disease in patients over age 2, with deamidated gliadin peptide (DGP) antibodies used as an alternative, particularly in young children or IgA-deficient patients.

Guiding treatment

Given its outdated status, a positive anti-gliadin IgA alone should not be relied upon for a celiac diagnosis; confirmatory tTG-IgA or DGP testing (and possibly biopsy) is warranted before starting a gluten-free diet.

Clinical significance

Low diagnostic accuracy per current guidelines; should not be used as a stand-alone celiac test today.

References
  1. AACC. (2023). Anti-Gliadin Antibody Assay — Optimal Testing Guide.
  2. AAFP. (2017). Comparative Accuracy of Diagnostic Tests for Celiac Disease.